|
|
|
| Efficacy of prednisone plus propylthiouracil in treatment of hyperthyroidism |
| CHEN Zhuo |
| The Third Medical Center of Chinese PLA General Hospital, Beijing 100039, China |
|
|
|
|
Abstract Objective To explore the efficacy of prednisone plus propylthiouracil in the treatment of hyperthyroidism.Methods Eighty patients with hyperthyroidism admitted to our hospital from January 2019 to June 2021 were selected as the research objects, and randomly divided into the control group and the observation group with 40 cases in each group according to the random number table method. The control group was treated with propylthiouracil, while the observation group was treated with propylthiouracil combined with prednisone. The total effective rate, calcium and phosphorus metabolism index, serum hormone level, quality of life score, liver and kidney function index and incidence of adverse reactions were compared between the two groups.Results The total effective rates of observation group and control group were 97.50% and 85.00% respectively, and the total effective rate of observation group was higher than that of control group (P<0.05). After treatment, the levels of blood calcium and phosphorus in the observation group were (1.95±0.20) mmol/L and (1.20±0.29) mmol/L respectively, which were lower than those in the control group (P<0.05). After treatment, the parathyroid hormone, free triodothyronine and free thyroxine in the observation group were (230.37±74.92) pg/ml, (12.86±3.57) pmol/L and (17.92±5.73) pmol/L respectively, which were lower than those in the control group (P<0.05), and the thyroid stimulating hormone in the observation group was (2.04±0.55) mU/L, which was higher than that in the control group (P<0.05). After treatment, the scores of physiology, psychology, environment and social relations in the quality of life in the observation group were (85.07±6.29), (84.98±5.97), (84.05±6.48) and (85.16±6.73) respectively, which were higher than those in the control group (P<0.05).Conclusions Prednisone combined with propylthiouracil has a good therapeutic effect on hyperthyroidism, which can effectively improve patients' thyroid function, correct the disorder of calcium and phosphorus metabolism and improve their quality of life. Moreover, the combined use of prednisone causes no obvious damage to patients' liver and kidney functions, and is characterized by good medication safety and few adverse reactions.
|
|
Received: 19 November 2021
|
|
|
|
|
|
| [1] |
Walasik S D, Kamiński G, Sudoł S I. Impact of radioiodine treatment on doppler flow parameters in the central retinal artery and ophthalmic artery in patients with hyperthyroidism[J]. J Ultrasound Med,2021,40(2):305-318.
|
| [2] |
Tulchinsky M, Brill A B. Spotlight on the association of radioactive iodine treatment with cancer mortality in patients with hyperthyroidism is keeping the highest risk from antithyroid drugs in the blind spot[J]. Clin Nucl Med,2019,44(10):789-791.
|
| [3] |
Azizi F, Abdi H, Cheraghi L, et al. Treatment of subclinical hyperthyroidism in the elderly: comparison of radioiodine and long-term methimazole treatment[J]. Thyroid,2021,31(4):545-551.
|
| [4] |
陈洪娇,张 娜,王丽娜,等.甲状腺功能亢进症患者生活质量及其影响因素分析[J].中华地方病学杂志,2021,40(3):235-239.
|
| [5] |
Tonacchera M, Chiovato L, Bartalena L, et al. Treatment of Graves' hyperthyroidism with thionamides: a position paper on indications and safety in pregnancy[J]. J Endocrinol Invest,2020,43(2):257-265.
|
| [6] |
Törring O, Watt T, Sjölin G, et al. Impaired quality of life after radioiodine therapy compared to antithyroid drugs or surgical treatment for Graves' hyperthyroidism: a long-term follow-up with the thyroid-related patient-reported outcome questionnaire and 36-item short form health status survey[J]. Thyroid,2019,29(3): 322-331.
|
| [7] |
赵 静,段莉莉,李 超.甲巯咪唑对甲状腺功能亢进症患者甲状腺激素水平及肝功能的影响研究[J].临床和实验医学杂志,2021,20(3):282-286.
|
| [8] |
Giesecke P, Frykman V, Wallin G, et al. All-cause and cardiovascular mortality risk after surgery versus versus radioiodine treatment for hyperthyroidism[J]. Br J Surg,2018,105(3):279-286.
|
| [9] |
岳德意.普萘洛尔分别联合丙硫氧嘧啶及甲巯咪唑治疗甲状腺功能亢进症的效果对比[J].河南医学研究,2021,30(6):1076-1078.
|
| [10] |
史晗冰,刘建光,徐靖华,等.知柏地黄口服液联合丙硫氧嘧啶辅治甲状腺功能亢进症的效果及对甲状腺激素、抗氧化指标的影响[J].临床误诊误治,2020,33(4):45-48.
|
| [11] |
毕婷婷,林庆焕,李晓帆,等.甲状腺功能亢进应用丙硫氧嘧啶联合比索洛尔治疗对患者TSH和TBil水平的影响[J].国际医药卫生导报,2021,27(17):2735-2738.
|
| [12] |
袁小燕,杨朝霞,李 为,等.丙硫氧嘧啶联合比索洛尔治疗甲状腺功能亢进患者的效果及其对肝功能、心功能的影响[J].疑难病杂志,2020,19(1):41-44.
|
| [13] |
徐金娥,解为慈.泼尼松联合丙硫氧嘧啶治疗甲状腺功能亢进症的临床研究[J].现代药物与临床,2019,34(12):3704-3707.
|
| [14] |
张娟娟.醋酸泼尼松联合甲巯咪唑治疗甲状腺功能亢进效果的短期随访[J].河南医学研究,2020,29(23):4348-4350.
|
| [15] |
刘丹阳,田丰秋,任丽媛,等.甲疏咪唑联合泼尼松治疗甲状腺功能亢进症患者临床安全性研究[J].中国现代药物应用,2019,13(21):101-103.
|
| [16] |
欧志雄.甲巯咪唑联合泼尼松治疗甲状腺功能亢进症的临床疗效及安全性观察[J].实用医技杂志,2018,25(6):635-636.
|
|
|
|
2022, Vol. 33 
